Tremelimumab plus Durvalumab Prior to Chemoradiotherapy in Unresectable Locally Advanced NSCLC, the Induction Trial

被引：0
|
作者：
Smeenk, M. M. [1 ]
van Diessen, J. N. A. [1 ]
Boellaard, T. N. [1 ]
Hartemink, K. J. [1 ]
de Vries, J. F. [1 ]
Badrising, S. K. [1 ]
Wondergem, M. [1 ]
Wittenberg, R. [1 ]
Monkhorst, K. [1 ]
van den Heuvel, M. M. [2 ]
Theelen, W. S. M. E. [1 ]
机构：
[1] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Induction; Immunotherapy; Locally advanced NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA16.03
引用
收藏
页码：S157 / S157
页数：1
相关论文
共 50 条
  • [1] Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non-Small Cell Lung Cancer: The Induction Trial
    Smeenk, Michiel M.
    van Diessen, Judi N. A.
    Boellaard, Thierry N.
    Hartemink, Koen J.
    de Vries, Jeltje F.
    van der Noort, Vincent
    Badrising, Sushil K.
    Owers, Emilia C.
    Monkhorst, Kim
    van den Heuvel, Michel M.
    Theelen, Willemijn S. M. E.
    CLINICAL CANCER RESEARCH, 2025, 31 (06) : 1037 - 1046
  • [2] Chemoradiotherapy Followed by Durvalumab in Unresectable Locally Advanced NSCLC- A Single Institution Experience in Croatia
    Gabelica, A. Bacelic
    Seiwerth, F.
    Bitar, L.
    Srdic, D.
    Maletic, O.
    Plestina, S.
    Samarzija, M.
    Jakopovic, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S275 - S275
  • [3] Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
    Kudo, Masatoshi
    HEPATOBILIARY SURGERY AND NUTRITION, 2022, 11 (04) : 592 - 596
  • [4] Efficacy of durvalumab after chemoradiotherapy with daily low-dose carboplatin for unresectable locally advanced NSCLC
    Kawajiri, Kazuki
    Shinno, Yuki
    Shirasawa, Masayuki
    Sato, Daiki
    Takeyasu, Yuki
    Torasawa, Masahiro
    Matsumoto, Yuji
    Masuda, Ken
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2022, 33 : S488 - S488
  • [5] Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
    Park, Sehhoon
    Oh, Dongryul
    Choi, Yoon-La
    Chi, Sang Ah
    Kim, Kyunga
    Ahn, Myung-Ju
    Sun, Jong-Mu
    CANCER, 2022, 128 (11) : 2148 - 2158
  • [6] Durvalumab after Radiochemotherapy for locally advanced unresectable NSCLC - a Breakthrough
    Guckenberger, Matthias
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (01) : 95 - 97
  • [7] Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma
    de Castria, Tiago Biachi
    Khalil, Danny N.
    Harding, James J.
    O'Reilly, Eileen M.
    Abou-Alfa, Ghassan K.
    FUTURE ONCOLOGY, 2022, 18 (33) : 3769 - 3782
  • [8] Induction Chemoimmunotherapy before Definitive Chemoradiotherapy for Large-Volume Unresectable Locally Advanced NSCLC
    Wang, Y.
    Zhang, T.
    Wang, J.
    Bi, N.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S266 - S267
  • [9] Radiotherapy plus durvalumab in locally advanced NSCLC: the DOLPHIN study
    Trommer, Maike
    STRAHLENTHERAPIE UND ONKOLOGIE, 2024, 200 (07) : 646 - 648
  • [10] A phase Ib trial of neoadjuvant/adjuvant durvalumab plus /- tremelimumab in locally advanced renal cell carcinoma (RCC).
    Ornstein, Moshe Chaim
    Zabell, Joseph
    Wood, Laura S.
    Hobbs, Brian
    Devonshire, Sarah
    Martin, Allison
    Allman, Kimberly D.
    Rao, Arpit
    Gilligan, Timothy D.
    Campbell, Steven
    Krishnamurthi, Venkatesh
    Rini, Brian, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345